PlainPharmaWatch

CMS Open Payments · Program Year 2024

Vero Biotech Inc.

Vero Biotech Inc. reported $4,408.17 across General Payments, Research, and Ownership to 9 physicians and teaching hospitals across 9 transactions.

See the rankings → How this is sourced
$4.4K
All-tracks total
9
Transactions
9
Recipients
−$23.6K
General Payments vs PY2023

Vero Biotech Inc. reported $4,408.17 across all CMS Open Payments tracks (General + Research + Ownership) to 9 physicians and teaching hospitals in Program Year 2024 - ranking #1727 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $4,408.17, averaging $489.80 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer vero-biotech-inc Vero Biotech Inc.

$4.4K · #1727/1,925 · 0.0% industry · PY2024

  • TOT $4.4K
  • RANK #1727
  • SHARE 0.0%
  • TXN 9
  • RCP 9
  • CAT 2
  • GEN $4.4K
  • ΔGEN −$23.6K
  • TOP1 83.7%
  • PY 2024

Volume peers

Nearest volume peer: Pajunk Medical Systems, LP ($4.4K)

VivaQuant Inc, dba Rhythm Ex…$4.5KPajunk Medical Systems, LP$4.4KVero Biotech Inc. (this)$4.4KCosa Medical, Llc$4.3KEnsemble Orthopedics, Inc$4.3K
All-tracks payment totals near Vero Biotech Inc. (CMS Open Payments PY2024)

Vero Biotech Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Vero Biotech Inc.'s CMS-reported General Payments decreased by $23.6K (−84.2%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: VERO BIOTECH INC.PY2023: VERO BIOTECH INC.PY2024: Vero Biotech Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$28.0KPY2024$4.4K
PY2023
$27,971.07
PY2024
$4,408.17

What the Data Shows for Vero Biotech Inc.

In Program Year 2024, Vero Biotech Inc. reported $4,408.17 in payments to 9 physicians and teaching hospitals across 9 individual transactions, an average of $489.80 per transaction and $489.80 per recipient. That total places Vero Biotech Inc. at rank #1727 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $3.7K across 1 transactions, 83.7% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Vero Biotech Inc. made 2 types of general payments. "Consulting Fee" is the largest category at $3.7K, 83.7% of General Payments.

How Vero Biotech Inc. divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$3.7K2. Food and Beverage$718.17
Payment Type Amount Transactions
Consulting Fee $3.7K 1
Food and Beverage $718.17 8

Recipient Concentration in General Payments

The five largest recipient relationships account for $4,220.14 (95.7%) of $4,408.17 in this company's General Payments records across 7 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Vero Biotech Inc.

The five named recipients with the highest reported General Payments from this company

Mark David Twite$3.7KJohn Wesley McConnell$218.53Puneeta Sarma Vasa$118.45Tiffany A Taylor$96.58Cynthia Mcclellan$96.58
  1. 1

    Mark David Twite

    $3,690.00 across 1 reported transactions

  2. 2

    John Wesley McConnell

    $218.53 across 2 reported transactions

  3. 3

    Puneeta Sarma Vasa

    $118.45 across 2 reported transactions

  4. 4

    Tiffany A Taylor

    $96.58 across 1 reported transactions

  5. 5

    Cynthia Mcclellan

    $96.58 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Vero Biotech Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Vero Biotech Inc..

Vital Connect, Inc

HHI 7052

Sebela Women's Health Inc.

HHI 7064

Accufix Surgical Inc.

HHI 7031

The Walman Optical Company

HHI 7106

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Vero Biotech Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Vero Biotech Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.